SCHEMBL12023732

CCOP(O)(=S)OC1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(O)(=S)O[C@H]1C[C@H](n2cnc3c2NCN=C3N)O[C@@H]1COP(O)(=S)O[C@H]1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(O)(=S)O[C@H]1C(OCCOC)[C@H](n2cnc3c(N)ncnc32)O[C@@H]1COP(O)(=S)OC1C(OCCOC)[C@H](n2cc(C)c(N)nc2=O)O[C@@H]1COP(O)(=S)O[C@H]1C(OCCOC)[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1COP(O)(=S)O[C@H]1C(OCCOC)[C@H](n2cnc3c(=O)[nH]c(N)nc32)O[C@@H]1COP(O)(=S)O[C@H]1C(OCCOC)[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1CO

nearest known ligand 0.48

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	F2	P00734	2/20	0.48

▸	DTYMK	P23919	4/20	0.45

▸	TERT	O14746	2/20	0.43

▸	RNASEL	Q05823	7/20	0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL12023746	0.94	F2 (0.53)	F2DTYMKTERTRNASEL
SCHEMBL12023795	0.91	F2 (0.54)	F2DTYMKTERTRNASEL
SCHEMBL10000624	0.90	F2 (0.54)	F2DTYMKTERTRNASEL
SCHEMBL29390498	0.89	F2 (0.55)	F2DTYMKTERTRNASEL
SCHEMBL12341642	0.89	F2 (0.55)	F2DTYMKTERTRNASEL
SCHEMBL682924	0.88	DTYMK (0.51)	F2DTYMKTERTRNASEL
SCHEMBL29406400	0.87	F2 (0.52)	F2DTYMKTERTRNASEL
SCHEMBL29384886	0.86	F2 (0.51)	F2DTYMKTERTRNASEL
SCHEMBL12023802	0.86	F2 (0.50)	F2DTYMKTERTRNASEL
SCHEMBL17589247	0.86	DTYMK (0.52)	F2DTYMKTERTRNASEL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20110301222-A1	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	ISIS PHARMACEUTICALS, INC. (US)	2011-12-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110301222-A1	COMBINATION THERAPY FOR THE TREATMENT OF CANCER	EIF5B, EIF2B5, EIF2B4	F2 4865/4885DTYMK 147/4885TERT 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.